Cardiovascular system assessment best practices: A safety pharmacology society meeting

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 855-866

  Cavero, Icilio ^a  

^a NONE   (Italy)

Author keywords

Assay design; Best practices; Cardiovascular system; Data summarization and analysis; Power analysis; Pro arrhythmia assessment; Safety pharmacology

Indexed keywords

CARDIOVASCULAR SYSTEM EXAMINATION; CONFERENCE PAPER; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; EXPERIMENTAL DOG; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; MORBIDITY; NONHUMAN; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; ST SEGMENT; TELEMETRY;

EID: 77955966772     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.510131     Document Type: Conference Paper

References (32)

1. ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/LOB/ media/MEDIA504.pdf
2. ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/LOB/ media/MEDIA2192.pdf
3. Available from: www.redbio.org/portal/ encuentros/enc-2001/conferencias/ C-23%20Pendiente%20en%20 conferencias/C-23.pdf
4. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010;55:567-574
5. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311(7003):485
6. Sivarajah A, Collins S, Sutton M, et al. Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power. J Pharmacol Toxicol Methods 2010; In press
7. Cavero I. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 2009;8:627-647
8. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45
9. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev 2002;5:116-126
10. Wallis RM. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 2010;159:115-121
11. Harmer SC, Wilson AJ, Aldridge R, Tinker A. Mechanisms of disease pathogenesisin long QT syndrome type 5. Am J Physiol Cell Physiol 2010;298:C263-73
12. Lawrence CL, Bridgland-Taylor MH, Pollard CE, et al. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 2006;149:845-860
13. Toyoshima S, Kanno A, Kitayama T, et al. PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 2005;99:459-471
14. Hanson LA, Bass AS, Gintant G, et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006;54:116-129
15. Klon AE. Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development. Expert Opin Drug Metab Toxicol 2010;6:821-833
16. Valentin JP, Bialecki R, Ewart L, et al. A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009;60:152-158
17. Trepakova ES, Koerner J, Pettit SD, et al. HESI Pro-Arrhythmia Committee. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 2009;60:45-50
18. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220
19. Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009;158:317-326
20. Holzgrefe HH, Cavero I, Gleason CR, et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs andcynomolgus monkeys. J Pharmacol Toxicol Methods 2007;55:159-175
21. Holzgrefe HH, Cavero I, Buchanan LV, et al. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. J Pharmacol Toxicol Methods 2007;55:227-237
22. Champeroux P, Martel E, Fowler JS, et al. Calculation of QT shift in non clinical safety pharmacology studies. J Pharmacol Toxicol Methods 2009;59:73-85
23. Van Der Linde HJ, Van Deuren B, Teisman A, et al. The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Pharmacol 2008;154:1474-1481
24. Cavero I. Safety Pharmacology Society: 9th Annual Meeting. Expert Opin Drug Saf 2010;9:365-378
25. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. Available from: www.ich.org/LOB/ media/MEDIA1476.pdf
26. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009;14:162-167
27. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959-968
28. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industrys grand challenge. Nat Rev Drug Discov 2010;9:203-214
29. Matthews EJ, Frid AA. Prediction of drug-related cardiac adverse effects in humans-A: creation of a database of effects and identification of factors affecting their occurrence. Regul Toxicol Pharmacol 2010;56:247-275
30. Frid AA, Matthews EJ. Prediction of drug-related cardiac adverse effects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul Toxicol Pharmacol 2010;56:276-289
31. Kirk B, Arvidson KB, Ronald Chanderbhan R, et al. Regulatory use of computational toxicology tools and databases at the United States Food and Drug Administrations Office of Food Additive Safety. Expert Opin Drug Metab Toxicol 2010;6:821-833
32. Pettit SD, Berridge B, Sarazan RD. A call for more integrated cardiovascular safety assessment. J Pharmacol Toxicol Methods 2010;61:1-2